Supernus Pharmaceuticals Inc. (SUPN)
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago.
